AbbVie vs ASML Holding: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AbbVie and ASML Holding side by side

1. 1984ASML Holding

   Founded as ASM Lithography in Eindhoven

   ASM Lithography starts operations on April 1, 1984 as a joint venture between Philips and ASM International, with the mandate to commercialize the PAS 2000 wafer stepper developed inside Philips.

2. 1986ASML Holding

   PAS 2500 stepper and the Carl Zeiss partnership

   ASML brings the PAS 2500 stepper to market with a new wafer alignment system developed by first chief scientist Steef Wittekoek, and establishes the optics partnership with Carl Zeiss that still supplies every ASML lithography system.

3. 1988ASML Holding

   ASM International withdraws and Philips funds a rescue

   With few customers and heavy cash consumption, ASM International decides to stop funding the joint venture while Philips launches a company-wide cost-cutting program.

4. 1991ASML Holding

   PAS 5500 platform turns the company around

   ASML launches the PAS 5500 platform, whose productivity and resolution win the first large orders from Intel and IBM under chief executive Willem Maris and take the company to profitability. PAS 5500 systems are still running in customer fabs decades later.

5. 1995ASML Holding

   IPO in Amsterdam and on Nasdaq

   ASML becomes a fully independent public company with a dual listing on the Amsterdam Stock Exchange and Nasdaq. Philips sells half of its shares at the IPO and divests the remainder over the following years.

6. 2001ASML Holding

   TWINSCAN platform launched and Silicon Valley Group acquired

   ASML introduces the TWINSCAN dual-stage architecture, which exposes one wafer while the next is measured and aligned, lifting throughput and overlay accuracy above competing systems.

7. 2003ASML Holding

   First immersion lithography system

   The TWINSCAN AT:1150i debuts as ASML's first immersion machine, projecting 193 nanometer light through a layer of ultrapure water between the lens and the wafer to raise resolution.

8. 2010ASML Holding

   First EUV prototype shipped

   ASML ships the TWINSCAN NXE:3100, its first extreme ultraviolet lithography tool, to the research facility of an Asian chipmaker.

9. 2012ASML Holding

   Customer Co-Investment Program with Intel, TSMC and Samsung

   Intel, TSMC and Samsung acquire newly issued ASML shares equal to an aggregate 23 percent minority stake for ~$4.35 billion (3.85 billion euros) in cash, and separately commit ~$1.56 billion (1.38 billion euros) of R&D funding over five years dedicated to EUV…

10. 2013AbbVie

    AbbVie Launches as an Independent Company

    AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.

11. 2013ASML Holding

    Cymer acquisition completed and second-generation EUV shipped

    ASML completes the acquisition of Cymer, the San Diego supplier of the light sources used in its lithography systems, in a cash-and-stock deal valued at ~$2.2 billion (1.95 billion euros) when it was agreed in October 2012.

12. 2015AbbVie

    Pharmacyclics Acquisition Completed

    AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.

13. 2017ASML Holding

    EUV enters high-volume manufacturing

    ASML begins shipping the production-ready TWINSCAN NXE:3400B after customers started ordering the NXE:3400 generation in batches in 2016, roughly two decades after EUV research began.

14. 2019AbbVie

    Skyrizi Receives Initial U.S. Approval

    The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.

15. 2019AbbVie

    Rinvoq Receives Initial U.S. Approval

    The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.

16. 2019ASML Holding

    Dutch government stops EUV exports to China

    The Netherlands does not renew ASML's export licence for EUV systems to China, the start of a widening export control regime.

17. 2020AbbVie

    Allergan Acquisition Completed

    AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.

18. 2023AbbVie

    U.S. Humira Biosimilar Competition Begins

    Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.

19. 2023ASML Holding

    First High-NA EUV system shipped

    ASML ships the first of its next-generation EUV systems with a numerical aperture of 0.55, the TWINSCAN EXE:5000, to Intel in Hillsboro, Oregon.

20. 2024AbbVie

    ImmunoGen Acquisition Completed

    AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.

21. 2024AbbVie

    Robert A. Michael Becomes CEO

    Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.

22. 2024AbbVie

    Cerevel Therapeutics Acquisition Completed

    AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.

23. 2024ASML Holding

    Christophe Fouquet becomes chief executive

    Peter Wennink and Martin van den Brink step down as presidents of ASML on April 24, 2024 and Christophe Fouquet becomes president, chief executive officer and chair of the Board of Management.

24. 2025AbbVie

    Robert A. Michael Becomes Chairman

    Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.

25. 2025AbbVie

    FY2025 Revenue Reaches $61.160 Billion

    AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.

26. 2025ASML Holding

    Record year, first EXE:5200B and Mistral AI investment

    ASML reports total net sales of ~$37 billion (32.7 billion euros), up 15.6 percent, net income of ~$10.8 billion (9.6 billion euros), a gross margin of 52.8 percent and 535 systems sold, and closes the year with a backlog of ~$43.8 billion (38.8 billion euros)…

27. 2026AbbVie

    Q1 2026 Revenue Reaches $15.002 Billion

    AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.

Acquisitions

Questions about AbbVie vs ASML Holding